Get started
Author

Wanning Xu

ORCID: 0009-0003-7338-4674
Observed ORCID: 0009-0003-7338-4674
OpenAlex ID: A5090835679
SAMETA: An open-label, three-arm, multicenter, phase III study of savolitinib + durvalumab versus sunitinib and durvalumab monotherapy in patients with MET-driven, unresectable, locally advanced/metastatic papillary renal cell carcinoma (PRCC).
2022 · Toni K. Choueiri, Wanning Xu, et al. · Journal of Clinical Oncology · 16
Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
2025 · James Chih-Hsin Yang, Yuh-Min Chen, et al. · Clinical Lung Cancer · 6
PP01.50 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
2024 · Zofia Piotrowska, Wanning Xu, et al. · Journal of Thoracic Oncology · 6
PDF
Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
2025 · Benjamin Philip Levy, Filippo de Marinis, et al. · Journal of Clinical Oncology · 4
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib
2024 · Colin Lindsay, Wanning Xu, et al. · Lung Cancer · 1
Abstract LB294: Baseline and on-treatment plasma-based genomics as a predictor of outcome in SAVANNAH: Savolitinib + osimertinib in EGFRm MET overexpressed/amplified NSCLC post-osimertinib
2023 · Ryan James Hartmaier, Aleksandra Markovets, et al. · Cancer Research · 1
Evaluation of MET Detection Methods and Cutoffs in EGFR -Mutated Non–Small Cell Lung Cancer following Disease Progression on Osimertinib in the Phase II SAVANNAH Study
2026 · Myung-Ju Ahn, Filippo de Marinis, et al. · Clinical Cancer Research
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib
2026 · Filippo de Marinis, Tae Min Kim, et al. · Future Oncology
Abstract LB416: SAVANNAH: Clearance of plasma EGFRm in patients with EGFRm MET-overexpressed (OverExp) and/or -amplified (Amp) NSCLC post-osimertinib (osi) treated with savolitinib (savo) + osi
2025 · Jonathan W. Riess, Filippo de Marinis, et al. · Cancer Research
Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi
2024 · James Chih-Hsin Yang, Yuh-Min Chen, et al. · Cancer Research
Works count: 10
Citation count: 34
H-index: 4
I10-index: 1
Year
Topic
Type